NCT00545545 2025-03-19
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
HiberCell, Inc.
Phase 1/2 Completed
HiberCell, Inc.
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
UNC Lineberger Comprehensive Cancer Center
University of Pittsburgh
University of Miami
University of Chicago
Merck KGaA, Darmstadt, Germany
Eli Lilly and Company